Brief: Boundless Bio Announces First Patient Dosed In First-in-Human Phase 1/2 Clinical Trial Of BBI-825 In Cancer Patients With Resistance Gene Amplifications
11/04/2024 15:17
April 11 (Reuters) - Boundless Bio Inc BOLD.O :
* BOUNDLESS BIO ANNOUNCES FIRST PATIENT DOSED IN
FIRST-IN-HUMAN
PHASE 1/2 CLINICAL TRIAL OF BBI-825 IN CANCER PATIENTS WITH
RESISTANCE GENE AMPLIFICATIONS
Source text for Eikon: ID:nBw6k7hDYa
Further company coverage: BOLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Boundless Bio
See all newsBoundless Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Boundless Bio Inc expected to post a loss of 58 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Bath & Body Works, Avis Budget, Cerebras
U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure
Boundless Bio soars on merger with Serapha